



IL-36 α Regulates Tubulointerstitial Inflammation in the Mouse Kidney

Osamu Ichii^{1*}, Junpei Kimura¹, Tadashi Okamura^{2,3}, Taro Horino⁴, Teppei Nakamura^{1,5}, Hayato Sasaki⁶, Yaser Hosny Ali Elewa^{1,7} and Yasuhiro Kon¹

¹Laboratory of Anatomy, Faculty of Veterinary Medicine, Department of Basic Veterinary Sciences, Hokkaido University, Sapporo, Japan, ²Department of Laboratory Animal Medicine, National Center for Global Health and Medicine, Tokyo, Japan, ³Department of Infectious Diseases, National Center for Global Health and Medicine, Tokyo, Japan, ⁴Department of Endocrinology, Metabolism and Nephrology, Kochi Medical School, Kochi University, Nankoku, Japan, ⁵Section of Biological Safety Research, Chitose Laboratory, Japan Food Research Laboratories, Chitose, Japan, ⁶Laboratory of Laboratory Animal Science and Medicine, School of Veterinary Medicine, Kitasato University, Towada, Japan, ⁷Faculty of Veterinary Medicine, Department of Histology and Cytology, Zagazig University, Zagazig, Egypt

OPEN ACCESS

Edited by:

Miriam Wittmann,
University of Leeds, United Kingdom

Reviewed by:

Lennart Matthias Roesner,
Hannover Medical School, Germany
Ankit Saxena,
National Institutes of Health (NIH),
United States

*Correspondence:

Osamu Ichii
ichi-o@vetmed.hokudai.ac.jp

Specialty section:

This article was submitted to
Inflammation,
a section of the journal
Frontiers in Immunology

Received: 08 August 2017

Accepted: 03 October 2017

Published: 23 October 2017

Citation:

Ichii O, Kimura J, Okamura T,
Horino T, Nakamura T, Sasaki H,
Elewa YHA and Kon Y (2017) IL-36 α
Regulates Tubulointerstitial
Inflammation in the Mouse Kidney.
Front. Immunol. 8:1346.
doi: 10.3389/fimmu.2017.01346

IL-36 α , a member of the IL-1 family, is a crucial mediator of inflammatory responses. We previously found that IL-36 α was overexpressed in injured distal tubules (DTs); however, its pathological function remains unclear. Herein, unilateral ureter obstruction (UJO) or folic acid (FA) injection was performed in mouse kidneys to assess the role of IL-36 α in kidney injury. IL-36 α mRNA and protein expression significantly increased in the kidneys within 24 h after UJO. IL-36 α localized to dilated DTs. IL-36 α expression significantly correlated with the progression of tubulointerstitial cell infiltration and tubular epithelium cell death in UJO kidneys and with renal dysfunction in FA-induced acute kidney injury mice. At 24 h after UJO, IL-36 α ⁺ DT epithelial cells showed loose intercellular digitations. IL-1RL2, an IL-36 α receptor protein, localized to podocytes, proximal tubules, and DTs in the healthy kidney. IL-1RL2 was expressed in interstitial cells and platelets or extended primary cilia of DT epithelial cells in UJO kidneys. IL-36 α stimulation promoted the production of IL-6 and Prss35, an inflammatory cytokine and collagen remodeling-associated enzyme, respectively, in cultured NIH3T3 fibroblasts. UJO-treated IL-36 α -knockout (KO) mice showed milder kidney injury features than wild-type (WT) mice did. In UJO kidneys from IL-36 α -KO mice, the expression of genes associated with inflammatory response and sensory perception was significantly different from that in WT mice. Altogether, our data indicate an association between intrarenal IL-36 α overexpression and the progression of tubulointerstitial inflammations and morpho-functional alterations of DT epithelial cells. IL-36 α may be a novel kidney injury marker useful for evaluating DT damages.

Keywords: inflammation, distal tubule, IL-36 α , tubulointerstitial lesion, unilateral ureter obstruction, folic acid

INTRODUCTION

Renal histopathology is divided into glomerular or tubulointerstitial lesions (TILs). Impairment of renal function correlates with the latter, which is considered a common pathway leading to renal fibrosis (1). TILs include several morphological changes of kidney tissues such as tubular dilations and cell death as well as interstitial cell infiltration. The features of TILs differ among diseases. Drug-induced acute kidney injury (AKI), caused by antibiotics or anticancer drugs, is characterized by severe injuries of proximal tubules (PTs) (2).

Although renal function is usually evaluated by analyzing serum levels of blood urea nitrogen (BUN) and creatinine (Cr) and urinalysis, these renal function biomarkers are insufficient to detect

early onset kidney diseases (3). Recent studies identified molecular markers of early renal dysfunction, inflammation, or cell damages (4, 5). Some markers were detected in whole urine and/or urinary exosomes, suggesting their potential as fluid biomarkers. Hepatitis A virus cellular receptor 1 (Havcr1, also known as Kim-1/Tim-1) and lipocalin 2 (Lcn2, also known as Ngal) are excellent markers to predict TILs in both AKI and chronic kidney disease (CKD) (4, 5).

Almost all biomarkers for TILs, including Kim-1 and Ngal, are overexpressed in PTs (4, 5). PTs are the longest segments in mammalian kidneys, and proliferation of parenchymal progenitor cells is mainly observed in the PTs among nephrons (6, 7). These data reflect the regenerative activity and capacity of PTs in response to renal injuries. In contrast, distal tubules (DTs) are relatively short segments, but crucial regulation centers for blood pressure and electrolytes. However, DT injury has not been fully examined nor distinguished from PT damages because excellent molecular markers for DT damages are lacking. Therefore, the proposed injury processes of renal tubules are based on those of PTs.

We recently demonstrated the upregulation of IL-1 family cytokines in the kidney of mouse CKD model (8–10). IL-1 family members are crucial mediators of inflammatory responses initiated from the rapid production of IL-1 family cytokines (11); therefore, these cytokines might have a potential as early mediators and markers for AKI. In fact, after surgery such as cardiopulmonary bypass, AKI was detected at 48–72 h due to serum Cr elevation. In contrast, urine level of IL-18, an intrarenal macrophage-derived IL-1 family cytokine, increased over 25-fold at 12 h and remained elevated up to 48 h after surgery (12). These data emphasize the advantages of IL-1 family members as markers of kidney diseases because of their rapid biological response to tissue injuries. IL-1 family member 6 (IL-1F6, also known as IL-36 α) is overexpressed in injured DTs from various mouse kidney diseases, including lupus nephritis, diabetic nephropathy, and traumatic kidney injury (8–10). Therefore, IL-36 α could be a useful marker of DT injury; however, its pathological function remains unclear.

In this study, we examined the pathological significance of IL-36 α during the progression of TIL using a unilateral ureter obstruction (UUO) model, folic acid (FA)-induced AKI model, and IL-36 α -knockout (KO) mice as well as *in vitro* analysis. We show that intrarenal IL-36 α overexpression is associated with renal dysfunction and the progression of TILs, including morpho-functional alteration of DT epithelial cells.

MATERIALS AND METHODS

Ethics Statement

Animal experimentation was approved by the Institutional Animal Care and Use Committee of the Graduate School of Veterinary Medicine, Hokkaido University (approval No. 16-0124). The investigators adhered to the Guide for the Care and Use of Laboratory Animals of Hokkaido University, Graduate School of Veterinary Medicine (approved by the Association for the Assessment and Accreditation of Laboratory Animal Care International).

Genome Editing

Two single guide RNA (sgRNA) designed for the target sequences (5'-CCTAGGGTCAATCTGCAGAT-3' and 5'-AGGGGGGATC CCACGTACAT-3'), and Cas9 mRNA were prepared as described previously (13). Briefly, an sgRNA expression vector with a T7 promoter was synthesized for the target sequence and transcribed *in vitro* using a MEGAshortscript kit (Life Technologies, Carlsbad, CA, USA). *hCas9* mRNA was synthesized using mMACHINE T7 kit (Life Technologies) and was polyadenylated with polyA tailing kit (Life Technologies). The purified *hCas9* mRNAs at 100 ng/mL and each sgRNAs at 50 ng/mL targeting exon 2 and exon 3 for *Il1f6* (coding gene of IL-36 α) were co-injected into the cytoplasm of the pronuclear stage eggs from C57BL/6N (B6; Japan SLC; Shizuoka, Japan), and the eggs were transferred into the oviducts of pseudopregnant ICR female mice. The founders were genotyped with primer pairs spanning the CRISPR/Cas9 cleaved site (Table S1 in Supplementary Material). The mutation of *Il1f6* gene was confirmed by sequencing analysis. To minimize the risk of off-target effects, the resulting founder (13) mouse was backcrossed to B6 mice for two generations, and the heterozygous IL-36 α -KO mice were then intercrossed to produce the homozygous IL-36 α -KO mice and wild-type (WT) mice that were used for this study. The genotype of the obtained littermates was confirmed by genotyping PCR analysis using specific primers for *Il1f6* mutation (Table S1 in Supplementary Material). The potential off-target site was predicted by CRISPR Design Tool (14) and listed in Table S2 in Supplementary Material.

UUO and FA-Induced AKI Models

B6 mice were used in all *in vivo* study. UUO operation was performed to male mice at 10 weeks of age or IL-36 α -KO mice at 4 weeks of ages. At 0–11 days after UUO, both kidneys and serum were collected. BrdU (100 mg/kg, i.p.) was injected to some mice 2 h before sampling. A part of each kidney was fixed in paraformaldehyde (PFA) or glutaraldehyde (GTA), and the remaining parts were stored at -80°C .

For the FA-induced AKI model, FA (800 mg/kg, i.p., Sigma-Aldrich; St. Louis, MO, USA) was injected to male B6 mice at 10 weeks of age. At 8 h after injection, the serum, urine, and kidneys were collected. A part of each kidney was fixed in 4% PFA, and the remaining parts were stored at -80°C . Urinary Cr was determined in FA models by the Creatinine Companion (Exocell; Philadelphia, PA, USA). Soluble proteins were extracted by using RIPA lysis buffer (Santa Cruz; Dallas, TX, USA) from urinary sediments and urinary exosomes. Urine (400 μL) was centrifuged at $21,000 \times g$ for 10 min, and its sediments and supernatants were used. Lithium dodecyl sulfate-sample buffer and sample reducing reagent (Thermo Fisher Scientific; Waltham, MA, USA) were added to the samples or directly added to urinary supernatant. The serum levels of BUN and Cr were measured with Fuji DriChem (Fujifilm Medical Co. Ltd.; Tokyo, Japan).

Cell Culture

M-1, MES13, NIH3T3, and AI cell lines [kindly provided from Dr. J.B. Kopp, National Institutes of Health (NIH)] were maintained as previously described (15, 16). Immortalized mouse PT cells (Figure S1 in Supplementary Material) and 209/MDCT

(American Type Culture Collection; Manassas, VA, USA) cells were maintained in REGM BulletKit (Lonza; Basel, Switzerland) and DMEM/F12 medium containing 10% fetal bovine serum (FBS) and 1 \times penicillin/streptomycin (PS; Thermo Fisher Scientific), respectively. For 209/MDCT, after stimulation by NaCl, KCl, H₂O₂, or LPS (Wako; Osaka, Japan) under FBS-free condition, cells were collected for RNA and protein analysis, or were fixed by using 4% PFA and stained by immunofluorescence method using IL-36 α antibody (Table S3 in Supplementary Material), phalloidin (Life Technologies), and Hoechst 33342 (Dojindo; Kumamoto, Japan). NIH3T3 cells were stimulated by recombinant mouse IL-36 α (7059-ML-010, R&D Systems; Minneapolis, MN, USA), and the culture medium and cells were collected for RNA and protein analysis. IL-6 in the culture medium was measured by ELISA (IBL; Gunma, Japan).

Microarray

Total RNA was extracted from frozen UUO and collateral control (Cont) kidneys of B6 mice at 7 days or WT and IL-36 α -KO mice at 48 h. One pooled sample collected from four kidneys was analyzed in each group. Gene expression was analyzed using a GeneChip Mouse Gene 2.0 ST Array (Affymetrix; Santa Clara, CA, USA). Microarray signals were normalized by using the RMA algorithm. Generic gene ontology (GO) term finder (<http://go.princeton.edu/cgi-bin/GOTermFinder>) was used for GO analysis.

Real-time PCR

Total RNA from frozen kidneys was isolated and used as a template to synthesize cDNA using ReverTra Ace qPCR RT Master Mix (Toyobo; Osaka, Japan). Quantitative PCR analysis was performed by using Brilliant III SYBR Master Mixes for kidneys (Agilent; Santa Clara, CA, USA) or TaqMan Real-Time PCR Master Mixes for cells (Thermo Fisher Scientific) and specific primers or probes (Table S1 in Supplementary Material) with an MX3000P system (Agilent). The specificity of each PCR reaction was confirmed by melting curve analysis. The expression data were normalized to the expression levels of *Actb* or *Gapdh*.

Immunoblotting

From collected kidneys, cells, and urines, soluble proteins were extracted by using RIPA lysis buffer (Santa Cruz). Lithium dodecyl sulfate-sample buffer and sample reducing reagent (Thermo Fisher Scientific) were added to the samples. Immunoblotting was performed by using the NuPAGE electrophoresis system (Thermo Fisher Scientific) with the antibodies listed in Table S3 in Supplementary Material. Immunocomplexes were detected by using Typhoon Variable-Mode Imagers (GE Healthcare; Little Chalfont, UK). The intensity of band was quantified using Image J (NIH).

Histopathology

Paraffin-embedded kidney sections were stained with periodic acid Schiff (PAS) or Masson's trichrome for histopathological analysis, and the area of renal pelvis (RP) was measured using ImageJ (NIH) or BZ-H3M (Keyence; Osaka, Japan). Sections were analyzed by immunohistochemistry or immunofluorescence

using primary antibodies listed in Table S3 in Supplementary Material as described previously (9, 16) and evaluated for the number of B220⁺ cells, Gr1⁺ cells, Iba1⁺ cells, single strand DNA (ssDNA)⁺ cells, Caspase 3⁺ cells, and IL-36 α ⁺ tubules. The signals detected in areas positive for CD3, BrdU, alpha-smooth muscle actin (α SMA), and IL-36 α were measured by using ImageJ (NIH) or BZ-H3M (Keyence).

Electron Microscopy

Four percent PFA/0.1 M phosphate buffer (PB) containing 2.5% GTA or 4% PFA/0.1 M containing 0.5% GTA was used for the fixation of transmission electron microscopy (TEM) and immunoelectron microscopy (IEM) specimens, respectively. For IEM, kidneys were fixed for 4 h, and PFA was replaced with 0.1 M PB containing 10–30% sucrose. The kidneys were incubated overnight, and then embedded by using O.C.T. Compound (Sakura Finetech; Tokyo, Japan). Immunohistochemistry using 5- μ m thick cryosections and streptavidin-biotinylated horseradish peroxidase complex (Nichirei; Tokyo, Japan) was performed to detect IL-36 α . TEM specimens and kidney sections for IEM were post-fixed with 1% OsO₄ and embedded in Quetol 812 (Nisshin EM; Tokyo, Japan), and the ultrathin sections were stained with or without uranyl acetate and lead citrate for TEM and IEM, respectively.

For scanning electron microscopy (SEM), specimens were fixed with 2.5% GTA/0.1 M PB and cut into 200- μ m sections by vibratome, and then post-fixed with OsO₄ and dehydrated in critical point drier (HCP-2; Hitachi, Tokyo, Japan). For IEM using SEM, specimens were fixed with 0.5% PFA and 0.25% GTA. Immunohistochemistry was performed to detect IL-36 α using 5- μ m thick paraffin sections, IL-36 α primary antibody, biotinylated secondary antibody, gold conjugated streptavidin-biotin, and gold enhance kit (Nanoprobe; Yaphank, NY, USA). After post-fixation by 0.5% OsO₄ and dehydration, ion-spattered sections were observed under SEM.


Statistical Analysis

The results are displayed as the mean \pm SE and were statistically analyzed by using a Mann–Whitney *U* test ($P < 0.05$). The correlation between two parameters was analyzed by using Spearman's rank correlation test ($P < 0.05$).

RESULTS

IL-36 α Is Produced by the Epithelium of DTs in UUO Kidneys

First, microarray analysis was performed in mouse kidneys at 7 days after UUO. Among the IL-1 family, *Il1f6* was the most upregulated gene in UUO kidneys; 2.67-fold vs. Cont kidneys (Figure 1A). Similar to *Kim-1*, *Il1f6* mRNA expression in the kidneys increased from 12 h after UUO, and its elevation was prominent at 24 h compared to that of other members (Figure 1B). At 12 h, *Il1rn*, *Il1f6*, *Il1f9*, and *Kim-1* mRNA expression was significantly higher in UUO kidneys than that in Control kidneys, but that of *Il18* and *Il1f5* was decreased (Figure 1C). At 24 h, *Il1rn*, *Il1f6*, and *Kim-1* mRNA expression was more significantly



increased in UUO kidneys. IL-36 α was detected in the kidneys from 24 h after UUO (Figure 1D).

In UUO kidneys, the dilated tubules were observed at 0.5–24 h after UUO (Figure 2A) and were positive for calbindin D28k, a DT marker. IL-36 α ⁺ immunostaining appeared in DTs, first in the macula densa (MD), from 12 h after UUO, and the immunostaining spread to surrounding DT segments at 24 h (Figures 2A,B). In DTs, IL-36 α ⁺ immunostaining was observed in the cytoplasm and in some nuclei (Figure 2B). Increased IL-36 α protein expression remained until 11 days after UUO without sex-related differences (Figures 2C,D). The number of IL-36 α ⁺ tubules increased from 12 h after UUO and was significantly higher in UUO kidneys than in Cont kidneys at 12 and 24 h (Figures 2E,F). In some Cont kidneys, a small number of cells were IL-36 α ⁺ in DTs, especially close to the MD (Figure 2G). The probability of IL-36 α ⁺ DT segments was significantly higher in DT segments attached to the renal corpuscle compared to the other DT segments in Cont kidneys; however, the latter DT segments showed higher values than the former DT segments in UUO kidneys (Figure 2H). These data indicated that DT segments attached to the renal corpuscle, including the MD, were initiation sites of IL-36 α expression, which spread to other DT segments as kidney injury progressed. At 24 h after UUO, IL-36 α expression was scarce in Cont kidneys, but clearly co-localized with calbindin D28k expression in UUO kidneys (Figure 2I).

Morphological Alteration of IL-36 α Expressing Epithelial Cells in UUO Kidneys

In TEM, the structures of PT epithelial cells remained normal after 24 h of UUO, but that of DT epithelial cells presented a dilated tubular lumen and squamous features (Figure 3A). IEM clarified that DT epithelial cells strongly expressing IL-36 α in the cytoplasm and nucleus showed loose intercellular digitations and randomized mitochondria arrangements (Figure 3B). IEM using SEM showed that IL-36 α ⁺ nanogold particles were observed in dilated DTs; These particles localized to the cytoplasm and nucleus as well as in extracellular regions beside the basement membrane and peritubular capillary (Figure 3C). Furthermore, long primary cilia were observed at the apical portion of DT epithelial cells in UUO kidneys rather than in Cont kidney at 48 h by SEM, and some of these cilia presented bulges and were interconnected (Figure 3D).

IL-36 α Overexpression Correlates with Renal Dysfunction in FA-Induced AKI Kidneys

After 8 h of FA injection, serum levels of BUN and Cr were significantly increased in the FA groups compared to that in the vehicle groups, and urinary Cr was significantly decreased in the former groups (Figure 4A). At 8 h after FA injection, *Il1rn* and *Il1f6* mRNA expression was significantly increased, but that of *Il1f5* and *Il1f8* was decreased in the kidneys of FA-AKI groups compared to that in the vehicle groups (Figure 4B). *Kim-1* mRNA expression also tended to increase after FA injection without statistical significance ($P = 0.062$). IL-36 α protein expression in the

kidneys was increased at 8 h after FA injection (Figures 4C–E), and IL-36 α ⁺ immunostaining was observed in DT epithelial cells as well as in luminal cell debris (Figure 4D). In the urine, IL-36 α protein was detected in the urinary sediment of FA-AKI individuals showing increased urinary cells suggested by increased β -actin expression, but not in their supernatant (Figure 4F, see #3, 6, 8). Table 1 summarizes the correlation between IL-36 α expression and renal dysfunction of the FA-AKI model. *Il1f6* mRNA expression significantly correlated with the serum levels of BUN and Cr and urinary Cr. IL-36 α protein expression also significantly correlated with serum level of BUN and urinary Cr.

IL-36 α Overexpression in UUO Kidneys Correlates with Interstitial Inflammation

The correlation between IL-36 α expression and kidney injury parameters was examined at 7 days after UUO because UUO kidneys at 7 days show severe interstitial inflammation. The ratio of kidney weight (KW)/body weight (BW) and the area of RP were significantly increased in UUO kidneys compared to those in Cont kidneys (Figures 5A,B). In UUO kidneys, infiltration of B220⁺ B-cells, CD3⁺ T-cells, Gr1⁺ granulocytes, and Iba1⁺ macrophages was observed at TILs (Figure 5C). Furthermore, BrdU⁺ proliferating cells and ssDNA⁺ or Caspase 3⁺ dead cells were detected in the tubular epithelium, and α SMA⁺ myofibroblasts increased. The quantified parameters, except for BrdU⁺ cells, and KW/BW, or the area of the RP, were significantly higher in UUO kidneys than in Cont kidneys (Figure 5D) and positively correlated with the number of IL-36 α ⁺ tubules (Table 2).

IL-36 α Is Induced by LPS and Stimulates IL-6 via IL-1RL2

IL-36 α induction was examined in 209/MDCT, a mouse DT epithelial cell line, and LPS stimulation for 24 h strongly induced IL-36 α mRNA and protein (Figures 6A–C).

Next, the expression of IL-1RL2, a receptor of IL-36 α , was examined in UUO kidneys at 48 h. IL-1RL2⁺ immunostaining was detected in PTs, podocytes, platelets, and interstitial cells (Figures 7A,B). Interestingly, dotted or rod-like IL-1RL2⁺ immunostaining was observed at the apical portion of the epithelial cells of DT, including the MD in UUO and Cont kidneys at 48 h (Figure 7A), indicating IL-1RL2 expression in primary cilia. At 12 and 24 h after UUO, *Il1rl2* mRNA expression tended to increase in UUO kidneys compared to that in Cont kidneys without statistical significance (Figure 7C). Among the examined mouse cell lines, *Il1rl2* mRNA expression was detected only in NIH3T3, a fibroblast line (Figure 7D). Therefore, IL-36 α stimulation was performed in NIH3T3 cells (Figure 7E). *Il1rl2* mRNA expression was not affected, but *Il6* mRNA expression in cell lysates and IL-6 protein level in the culture medium significantly increased from 6 h after IL-36 α stimulation.

IL-36 α -KO Mice Show Mild TILs in UUO Kidney

Parts of exon 2 and exon 3 were deleted by the CRISPR/Cas9 system to generate IL-36 α -KO mice (Figure 8A). At 48 h after UUO, KO mice expressed no IL-36 α (Figure 8B). KW/BW, KW




FIGURE 2 | Protein expression and localization of IL-36 α in unilateral ureter obstruction (UUO) kidneys. **(A)** Renal histopathology after UUO. In periodic acid Schiff staining, dilated distal tubules (DTs) are observed from 0.5 h after UUO (arrows). Positive immunostaining for calbindin D28k, a DT marker, is observed in DTs, and almost all of them were dilated from 0.5 h after UUO (arrows). IL-36 α immunostaining is observed in DTs, especially in the macula densa (MD), from 12 h after UUO (arrows). This immunostaining spreads to the entire DTs at 24 h after UUO. **(B)** Immunohistochemistry for IL-36 α in the UUO kidney at 24 h after UUO. IL-36 α immunostaining is observed in the cytoplasm, and some nuclei are also stained. **(C)** Immunohistochemistry for IL-36 α in the UUO kidney at day 11 after UUO. IL-36 α tubules are numerous in UUO kidneys compared to Cont kidneys. **(D)** The number of IL-36 α tubules in Cont and UUO kidneys. Values = mean \pm SE. A significant difference from the Cont in same sexes is indicated by * ($P < 0.05$) or ** ($P < 0.01$). No sex-related difference is detected. $n = 5$ (kidneys). **(E)** Time course of IL-36 α tubule number in Cont and UUO kidneys. **(F)** The number of IL-36 α tubules in Cont and UUO kidneys. Values = mean \pm SE. A significant difference from the Cont is indicated by * ($P < 0.05$) or ** ($P < 0.01$). A significant difference between 12 h in the same group is indicated by † ($P < 0.05$) or †† ($P < 0.01$). $n \geq 5$ kidneys. **(G)** Immunohistochemistry for IL-36 α tubules in Cont kidney. In a few Cont kidneys, IL-36 α immunostaining is occasionally observed in the MD at 24 h after UUO (arrows). **(H)** Probability of IL-36 α tubules in DT segments attached to the renal corpuscles and the other DT segments. Values = mean \pm SE. A significant difference from others is indicated by * ($P < 0.05$) or ** ($P < 0.01$). A significant difference between Cont kidneys and UUO kidneys in the same group is indicated by † ($P < 0.05$) or †† ($P < 0.01$). $n = 5$ (kidneys). **(I)** Immunofluorescence for calbindin D28k and IL-36 α . No IL-36 α staining is detected in Cont kidney. In UUO at 24 h, dilated calbindin D28k $^{+}$ tubules (green, large arrow) are also positive for IL-36 α (yellow, arrowheads), and some of them show decreased calbindin D28k $^{+}$ staining (red, small arrows).




FIGURE 3 | Continued

FIGURE 3 | Continued

Morphological characteristics of IL-36 α expressing epithelial cells in unilateral ureter obstruction (UJO) kidneys. **(A)** Transmission electron microscopy images of the kidneys at 24 h after UJO. Proximal tubule (PT) epithelial cells show normal structures in UJO kidneys. Distal tubule (DT) epithelial cells show well-developed basal infolding and regular mitochondria arrangement in Cont kidneys. In DTs of UJO kidneys, dilated tubular lumen, squamous feature, vacuolar structures, randomized mitochondria arrangement and basal infolding, and lamellar structures in the lumen are observed in epithelial cells. Lu, lumen. **(B)** Immunoelectron microscopy (IEM) images of the kidney at 24 h after UJO. No positive reaction is observed in IgG-isotype control staining. The DT epithelial cells strongly stained for IL-36 α in the cytoplasm and nucleus (arrowhead) showed loose interdigitation, randomized mitochondria arrangement, and basal infolding (arrows). BM, basement membrane; Lu, lumen; Cap, peritubular capillary; Nuc, nucleus. **(C)** IEM images of the kidney at 48 h. For IEM using scanning electron microscopy (SEM), IL-36 α ⁺ nanogold particles are observed in dilated DTs, and these particles localize to the cytoplasm and nucleus as well as extracellular regions beside the BM (arrow) and peritubular capillary, and they are scarce in PTs. Lu, lumen; Cap, peritubular capillary; Nuc, nucleus. **(D)** Ultrastructure of Cont and UJO kidneys at 48 h under SEM. In Cont kidneys, DT epithelial cells showed well-developed basal infoldings and narrow lumens. In UJO kidneys, DT epithelial cells showed dilated lumen and long primary cilia (arrows), and some of them showed connections (insets) and bulge structure (arrowheads).




TABLE 1 | Relationship between IL-36 α expression and renal dysfunction in the folic acid (FA)-induced AKI model.

Indices	FA-induced AKI model			
		Renal function		
		Blood urea nitrogen	Serum creatinine (Cr)	Urinary Cr
Kim-1 mRNA	ρ	0.660	0.850	-0.660
	<i>P</i>	0.018*	0.016*	0.020*
	<i>N</i>	12	7	12
Il1f6 mRNA	ρ	0.660	0.780	-0.830
	<i>P</i>	0.020*	0.041*	0.01<***
	<i>N</i>	12	7	12
IL-36 α protein	ρ	0.880	0.685	-0.710
	<i>P</i>	0.01<***	0.090	0.010*
	<i>N</i>	12	7	12

Male B6 mice at 10 weeks of age were analyzed after FA injection for 8 h. ρ ,

Spearman's rank correlation coefficient.

**P* < 0.05.

***P* < 0.01.

ratio (UUO/Cont), BUN, and serum Cr, were significantly higher at 48 h in the UUO group than in the Sham group in both WT and KO mice (Figure 8C). However, serum potassium concentration was significantly increased in the UUO group of WT mice, but not in that of KO mice compared with each Sham group, and a significant difference was observed between WT and KO mice in the UUO group. CD3⁺ T-cells and Gr1⁺ granulocytes were detected in 48 h UUO kidney in both WT and KO mice (Figure 8D), but infiltration of these cells and renal tubule dilation were significantly milder in UUO kidneys of KO mice than in WT mice (Figure 8E).

Table 3 summarized the GO analysis of genes differently expressed in the kidneys of WT and KO mice at 48 h after UUO. Genes involved in inflammatory response and acute inflammatory response were significantly downregulated (under 1.5-fold, *P* < 0.01) in the kidneys of KO mice compared to that in the kidneys of WT mice. Further, genes involved in sensory perception or detection of chemicals were significantly upregulated or downregulated (over or under 1.5-fold, *P* < 0.01). In particular,





TABLE 2 | Relationship between IL-36 α ⁺ tubule numbers and pathological indices in unilateral ureter obstruction (UUO) kidneys.

Indices	Weights of body and kidneys		Infiltration of immune cells				Proliferation or death of cells			Fibrosis and dilation of RP		
	BW	KW/BW	B220 ⁺	CD3 ⁺	Gr1 ⁺	Iba1 ⁺	BrdU ⁺	Caspase3 ⁺	ssDNA ⁺	α SMA ⁺	RP	
IL-36 α ⁺ tubules	ρ	0.086	0.741**	0.748**	0.860**	0.783**	0.832**	0.371	0.839**	0.792**	0.727**	0.832**
	<i>P</i>	0.872	0.006	0.005	0.001<	0.003	0.001	0.236	0.001	0.002	0.007	0.001

Male C57BL/6N mice at 10 weeks of age were analyzed at day 7 after UUO.

KW, kidney weight; BW, body weight; BrdU, bromodeoxyuridine; ssDNA, single strand DNA; SMA, smooth muscle actin; RP, renal pelvis; ρ , Spearman's rank correlation coefficient.

***P* < 0.01. N = 6. Six control and six UUO kidneys were analyzed.



genes belonging to the olfactory receptor (Olfir) and vomeronasal receptor (Vmnr) family were frequently downregulated or upregulated (Figure S2 in Supplementary Material).

IL-1F6/IL-36 α Stimulates IL-6 and Prss35 Productions via IL-1RL2

Figure 9A summarizes the genes differentially expressed in the kidneys of WT and IL-36 α -KO mice at 48 h after UUO in microarray analysis. In particular, protease serine 35 (Prss35) mRNA expression was decreased in KO mice, suggesting Prss35 as a candidate downstream molecule of IL-36 α signaling. NIH3T3 stimulated by IL-36 α showed increased Prss35 mRNA and protein expression (Figures 9B–F), and Prss35⁺ immunostaining was detected in interstitial fibroblasts and DTs of UUO kidneys (Figure 9G).

DISCUSSION

In this study, IL-36 α was the most upregulated gene in UUO mouse kidneys among IL-1 family members. IL-36 α belongs to the IL-36 subfamily, including IL-1F8/IL-36 β , IL-1F9/IL-36 γ , and IL-1F5 (IL-36 receptor antagonist; IL-1F5/IL-36Ra) in

humans (17, 18). Various epithelial cells express IL-36 cytokines, which activate NF- κ B and MAPK pathways and promote inflammatory responses in respiratory diseases, arthritis, or dermatitis (17–20). Our results revealed that *Il1f6* and *Il1rn* mRNA expression increased, but that of *Il1f5* and *Il1f8* decreased in the mouse kidneys injured by UUO and FA. Therefore, IL-1 family members coordinately alter their transcriptional status to maintain the balance between activation and inhibition of inflammation.

The present study demonstrates the significant correlation between IL-36 α expression and TIL scores, indicating that IL-36 α plays a crucial role in TIL progression. Furthermore, IL-36 α localized to DTs, and DT segments, including the MD, were suggested as the initiation sites of IL-36 α production in the early response to kidney injury. There is no clear evidence about cytokines being expressed in the MD; however, cyclooxygenase 2, a strong inducer of cytokines via the arachidonic acid cascade, is constitutively expressed in the MD, indicating its potentials as an inflammatory regulator (21, 22).

Our *in vitro* study revealed that LPS, a toll-like receptor ligand, induced IL-36 α production in 209/MDCT, suggesting that the activation of NF- κ B or MAPK pathways (23) via toll-like receptor might be an upstream event of IL-36 α induction. Furthermore,




FIGURE 7 | IL-1RL2 expression in the mouse kidney and induction of IL-6 production by IL-36 α stimulation *in vitro*. **(A)** Immunofluorescence for IL-36 α and IL-1RL2 in Cont and unilateral ureter obstruction (UUO) kidneys at 48 h. Green, red, and blue indicate IL-1RL2, IL-36 α , and nuclei, respectively. Arrows indicate the dotted or linear IL-1RL2⁺ reactions. G, glomerulus; Lu, lumen. **(B)** Immunofluorescence for IL-36 α and IL-1RL2 in Cont and UUO kidneys at 48 h. Green, red, and blue indicated IL-1RL2, IL-36 α , and nuclei, respectively. Arrows and arrowheads indicate the IL-1RL2⁺ interstitial cells and platelets, respectively. G, glomerulus. **(C)** Relative mRNA expression of *Il1rl2* in Cont and UUO kidneys. Values = mean \pm SE. $n \geq 4$ (kidneys). **(D)** Relative mRNA expression of *Il1rl2* in mouse cell lines. Values = mean \pm SE. $n = 4$. A significant difference with other cell lines is indicated by **($P < 0.01$). Mes, mesangial; Epi, epithelial; CD, collecting duct; Fibro, fibroblast. **(E)** Relative mRNA expression of *Il1rl2* and *Il6* and medium IL-6 levels in IL-36 α -exposed NIH3T3 cells. Values = mean \pm SE. $n = 4$. A significant difference with 0 h is indicated by *($P < 0.01$) or **($P < 0.01$).

IL-1RL2 localized to renal epithelial cells, interstitial cells, and platelets in the mouse kidney. IL-36 α increases in serum from patients with inflammatory disease such as Sjögren's syndrome (24, 25) and in the urine of patients with TILs (26). Our IEM observation also indicated IL-36 α excretion from the injured DT epithelium; therefore, these IL-1RL2-expressing cells receive IL-36 α signals directly in a paracrine/autocrine manner or indirectly *via* the urine and blood. In the examined cell lines, NIH3T3 fibroblasts showed *Il1rl2* expression and produced IL-6 in response to IL-36 α stimulation. Thus, we speculate that interstitial fibroblasts participate in the IL-36 α -IL-1RL2/IL-6 cascade.

Importantly, IL-1RL2 localization was clear at expanded cilia of DT epithelial cells after UUO. Therefore, *in vivo*, disease conditions might be important to maintain IL-1RL2 cellular expression.

IL-36 α -KO mice presented milder kidney disease features than WT mice after UUO, including serum potassium levels and TILs. DTs are important segments for potassium excretion, and increased serum potassium levels were noted in both CKD and AKI (27). Furthermore, GO analysis confirmed decreased gene expression patterns associated with the inflammatory response in the IL-36 α -KO kidneys. Therefore, the data obtained with KO mice indicated the attenuation of renal dysfunction and




FIGURE 8 | Renal pathology in unilateral ureter obstruction (UUO)-treated IL-36 α -knockout (KO) mice. **(A)** Genomic structure of IL-36 α . Parts of exon 2 and exon 3 are deleted by CRISPR/Cas9 system to generate IL-36 α -KO mice. **(B)** Immunohistochemistry for IL-36 α in the kidneys of wild-type (WT) and IL-36 α -KO mice at 48 h after UUO. **(C)** Indices for renal pathology and function in Sham and UUO groups at 48 h. Median. Box = 25th and 75th percentiles. Bars = min and max values. A significant difference between the Sham group in same genotype is indicated by * ($P < 0.05$) or ** ($P < 0.01$). A significant difference between WT and IL-36 α -KO in UUO group is indicated by † ($P < 0.05$). $n \geq 7$ mice. The ratio of UUO kidney weight (KW) to Cont KW is expressed as KW ratio (UUO/Cont). **(D)** Renal histopathology at 48 h after UUO. Immunohistochemistry and periodic acid Schiff (PAS) stain. In PAS staining, the dilation of distal tubules (DTs) (circles) was milder in UUO kidneys compared to WT kidneys after UUO. **(E)** Indices for renal histopathology in Cont kidney and UUO kidney of WT and IL-36 α -KO mice. Median. Box = 25th and 75th percentiles. Bars = min and max values. A significant difference from the Sham group in the same genotype is indicated by * ($P < 0.05$) or ** ($P < 0.01$). A significant difference between WT and IL-36 α -KO in UUO group is indicated by †† ($P < 0.01$) ($n \geq 7$ mice).

TABLE 3 | Gene ontology (GO) analysis of genes showing altered expression in the kidneys of wild-type (WT) and IL-36 α knockout (KO) mice after unilateral ureter obstruction (UUO) at 48 h.

Comparison	Ontology aspects	GO term	Cluster frequency (%)	Genome frequency (%)	Corrected P-value
Downregulated genes in UUO-treated kidney of IL-36 α -KO mice	Process	Inflammatory response	8.50	2.50	0.00088
		Acute inflammatory response	3.50	0.50	0.0056
		G-protein coupled receptor signaling pathway	17.40	7.80	0.00044
		Sensory perception	15.80	7.60	0.00931
	Function	Signaling receptor activity	17.40	8.50	0.00086
		Signal transducer activity	18.90	9.70	0.00103
		Receptor activity	18.10	9.40	0.00217
		Molecular transducer activity	18.10	9.40	0.00217
		Transmembrane signaling receptor activity	16.20	8.20	0.00334
		Transmembrane receptor activity	16.20	8.30	0.00548
	Component	NA			

Two hundred and fifty nine genes were downregulated in the kidneys of IL-36 α -KO mice compared with that that in the kidneys of WT mice; 24,424 genes were examined; Bonferroni correction for *P*-values. NA: not annotated

Upregulated genes in UUO-treated kidney of IL-36 α -KO mice	Process	Sensory perception of chemical stimulus	29.00	5.90	1.50E-34
		Sensory perception of smell	23.80	4.60	1.28E-28
		Sensory perception	30.00	7.60	1.96E-28
		Neurological system process	31.60	9.20	1.01E-25
		G-protein coupled receptor signaling pathway	27.40	7.80	4.29E-22
		System process	33.20	11.70	9.47E-21
		Detection of chemical stimulus involved in sensory perception	5.20	1.20	0.00132
		Detection of chemical stimulus	5.20	1.30	0.0041
		Signal transduction	34.90	23.50	0.00418
		Multicellular organismal process	44.60	32.70	0.0079
	Function	Olfactory receptor activity	23.80	4.50	5.13E-30
		Receptor activity	31.30	9.40	7.54E-25
		Molecular transducer activity	31.30	9.40	7.54E-25
		Transmembrane signaling receptor activity	29.00	8.20	8.46E-25
		Transmembrane receptor activity	29.00	8.30	3.76E-24
		Signaling receptor activity	29.00	8.50	2.26E-23
		Signal transducer activity	29.30	9.70	4.62E-20
		Odorant binding	10.70	1.90	1.16E-13
		Pheromone binding	2.60	0.40	0.00356
		Serine-type endopeptidase inhibitor activity	2.90	0.50	0.00365
		Endopeptidase inhibitor activity	3.60	0.80	0.00506
		Endopeptidase regulator activity	3.60	0.80	0.00708
		Peptidase inhibitor activity	3.60	0.80	0.00814
		G-protein coupled receptor activity	6.80	2.60	0.00961
	Component	Integral component of membrane	37.50	23.40	2.69E-06
		Intrinsic component of membrane	37.80	24.00	6.19E-06
		Membrane part	39.10	28.60	0.00736

Three hundred seven genes were upregulated in the kidneys of IL-36 α -KO mice compared to that in the kidneys of WT mice; 24,424 genes were examined; Bonferroni correction for *P*-values

inflammation because of IL-36 α deficiency from DTs. Importantly, Prss35 increased in UUO mouse kidney and fibrosis-associated fibroblasts (28). Moreover, Prss35 expression decreased in UUO kidneys of IL-36 α -KO mice compared with WT mice. Further, Prss35 significantly increased after IL-36 α stimulation in cultured fibroblasts, suggesting Prss35 as a novel downstream molecule of IL-36 α . Prss35⁺ immunostaining was detected in the interstitial fibroblasts of UUO kidneys and was reported as a regulator of renal fibrosis *via* collagen degradation (28). Thus, IL-36 α may regulate inflammation and the remodeling of tubulointerstitial structures *via* Prss35 production.

A recent study reported the amelioration of TILs *via* the NLRP3 inflammasome and IL-23/IL-17 axis in UUO kidneys

of IL-1RL2-KO mice (26). This phenotypic amelioration in these receptor-KO mice was more drastic than our data using ligand-KO mice. Additionally, *Il23a* and *Il17a* gene expression in UUO kidneys was similar in WT and IL-36 α -KO mice in microarray analysis (1.24-fold and 1.02-fold, compared with WT mice, respectively). IL-1RL2 can also bind to IL-1F8/IL-36 β and IL-1F9/IL-36 γ (18, 19). Therefore, these family members might compensate the lack of IL-36 α in UUO kidney of KO mice.

Interestingly, epithelial cells of dilated DT showed expanded primary cilia, and the gene expression patterns of *Olfr* and *Vmnr* in UUO kidneys were significantly altered between WT and IL-36 α -KO mice. Numerous family members of these sensory proteins were identified (over 1,000 members of




FIGURE 9 | Induction of Prss35 by IL-36 α stimulation *in vitro* and unilateral ureter obstruction (UUO) kidneys *in vivo*. **(A)** Genes downregulated (twofold down) in microarray in the kidneys of IL-36 α - knockout (KO) mice compared with that in WT mice at 48 h after UUO. **(B)** Relative mRNA expression of genes downregulated in panel **(A)** in IL-36 α -exposed NIH3T3 cells. Values = mean \pm SE ($n = 4$). A significant difference with 0 h is indicated by * ($P < 0.05$). **(C)** mRNA expression of *Prss35* in IL-36 α -exposed NIH3T3 cells. **(D)** Relative mRNA expression of *Prss35* in IL-36 α -exposed NIH3T3 cells. Values = mean \pm SE ($n = 4$). A significant difference with 0 h is indicated by * ($P < 0.05$). **(E)** Immunoblotting for Prss35 and β -actin using cell lysates from NIH3T3 cells after IL-36 α exposure for 0 and 48 h. **(F)** Prss35 levels in cell lysate from IL-36 α -exposed NIH3T3 cells. Values = mean \pm SE ($n = 4$). A significant difference with 0 h is indicated by * ($P < 0.05$). **(G)** Immunohistochemistry for Prss35 in Cont and UUO kidneys of WT mice. Prss35 $^{+}$ staining was strong in interstitial fibroblasts in the kidneys of UUO at 4 days after operation. No positive reaction is observed in IgG-isotype control staining.

Olfir in mice); these proteins localize to the cilia on the tips of olfactory sensory neurons, recognizing various ligands such as short chain fatty acids (29). Consistently, the kidney expresses Olfir family members, and some of them participate in blood pressure regulation *via* the renin–angiotensin system (29). Importantly, UO for 8 days caused injury and dilation of DTs accompanied with a significant increase of cilial length (30, 31). IL-1RL2 was detected at the cilium of epithelial cells of dilated DTs in the UO kidney; therefore, expanded cilia of DT cells may increase their sensitivity to urine flow and ligands, including IL-36 α , to alter their morpho-function in response to injury.

IL-36 α expression was positively correlated with serum levels of BUN and Cr in FA-induced AKI models. The *P* and ρ values of IL-36 α expression with these parameters were comparable to those of Kim-1. Kim-1 and Ngal are PT-derived excellent makers for kidney injuries (4, 5). An increase in IL-36 α was reported in the urine from patients with TILs (26). Our study showed that urinary sediments from FA-induced AKI mice contained IL-36 α . Importantly, IL-36 α is also strongly expressed in the epithelium of the skin, esophagus, thymus, and uterus, showing normal histology without inflammation in healthy mice (8). N-terminal processing is required for full agonist activity of IL-36 α protein (32). IL-36 family members are activated by protease such as neutrophil granule-derived proteases (32, 33). Therefore, accelerated enzymatic processing may also be required to induce kidney diseases. Furthermore, IL-36 α was also detected in the nuclei of injured DT epithelial cells. The nuclear translocation was also reported for IL-1 α and IL-33, indicating their function in the transcriptional regulation of other cytokines (34). To solve these limitations, the accurate level of urine IL-36 α should be determined by developing an ELISA system and candidate enzymes for intrarenal IL-36 α processing as well as the function of nuclear IL-36 α in kidney disease should be clarified.

In conclusion, IL-36 α overexpression in DT is closely associated with the progression of tubulointerstitial inflammation. DTs are crucial regulation centers for blood pressure and electrolytes. The detection of DT damage focusing on IL-36 α expression and combination with that of PT damages by using Kim-1 and Ngal

in the kidney could lead to more accurate and earlier histopathological evaluation of kidney injuries.

ETHICS STATEMENT

Animal experimentation was approved by the Institutional Animal Care and Use Committee of the Graduate School of Veterinary Medicine, Hokkaido University (approval No. 16-0124). The investigators adhered to the Guide for the Care and Use of Laboratory Animals of Hokkaido University, Graduate School of Veterinary Medicine (approved by the Association for the Assessment and Accreditation of Laboratory Animal Care International).

AUTHOR CONTRIBUTIONS

OI and HS conceived and performed experiments and analyzed data. OI, JK, TH, YE, and YK conceived experiments. TO and TN created knockout mice and analyzed data, respectively. All authors were involved in writing the paper and had final approval of the manuscript.

ACKNOWLEDGMENTS

A part of mouse samples was kindly provided by Dr. Akira Yabuki, Kagoshima University, Japan.

FUNDING

This work was partially supported by grants from Inamori Foundation, Kazato Research Grants, and JSPS KAKENHI Grant Numbers 13J00961 and 15K14873 and by Grants-in Aid for Research from the National Center for Global Health and Medicine (26-105 and 29-1001).

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at <http://www.frontiersin.org/article/10.3389/fimmu.2017.01346/full#supplementary-material>.

REFERENCES

- Nangaku M. Mechanisms of tubulointerstitial injury in the kidney: final common pathways to end-stage renal failure. *Intern Med* (2004) 43:9–17. doi:10.2169/internalmedicine.43.9
- Oni L, Hawcutt DB, Turner MA, Beresford MW, McWilliam S, Barton C, et al. Optimising the use of medicines to reduce acute kidney injury in children and babies. *Pharmacol Ther* (2017) 174:55–62. doi:10.1016/j.pharmthera.2017.02.018
- Waikar SS, Betensky RA, Bonventre JV. Creatinine as the gold standard for kidney injury biomarker studies? *Nephrol Dial Transplant* (2009) 24:3263–5. doi:10.1093/ndt/gfp428
- Wasung ME, Chawla LS, Madero M. Biomarkers of renal function, which and when? *Clin Chim Acta* (2015) 438:350–7. doi:10.1016/j.cca.2014.08.039
- Fassett RG, Venuthurupalli SK, Gobe GC, Coombes JS, Cooper MA, Hoy WE. Biomarkers in chronic kidney disease: a review. *Kidney Int* (2011) 80:806–21. doi:10.1038/ki.2011.198
- Maeshima A, Sakurai H, Nigam SK. Adult kidney tubular cell population showing phenotypic plasticity, tubulogenic capacity, and integration capability into developing kidney. *J Am Soc Nephrol* (2006) 17:188–98. doi:10.1681/ASN.2005040370
- Yang HC, Liu SJ, Fogo AB. Kidney regeneration in mammals. *Nephron Exp Nephrol* (2014) 126:50. doi:10.1159/000360661
- Ichii O, Otsuka S, Sasaki N, Yabuki A, Ohta H, Takiguchi M, et al. Local overexpression of interleukin-1 family, member 6 relates to the development of tubulointerstitial lesions. *Lab Invest* (2010) 90:459–75. doi:10.1038/labinvest.2009
- Kimura J, Ichii O, Miyazono K, Nakamura T, Horino T, Otsuka-Kanazawa S, et al. Overexpression of toll-like receptor 8 correlates with the progression of podocyte injury in murine autoimmune glomerulonephritis. *Sci Rep* (2014) 4:7290. doi:10.1038/srep07290
- Shiozuru D, Ichii O, Kimura J, Nakamura T, Elewa YH, Otsuka-Kanazawa S, et al. MRL/MpJ mice show unique pathological features after experimental kidney injury. *Histol Histopathol* (2016) 31:189–204. doi:10.14670/HH-11-662

11. Garlanda C, Dinarello CA, Mantovani A. The interleukin-1 family: back to the future. *Immunity* (2013) 39:1003–18. doi:10.1016/j.immuni.2013.11.010
12. Parikh CR, Mishra J, Thiessen-Philbrook H, Dursun B, Ma Q, Kelly C, et al. Urinary IL-18 is an early predictive biomarker of acute kidney injury after cardiac surgery. *Kidney Int* (2006) 70:199–203. doi:10.1038/sj.ki.5001527
13. Nitta T, Muro R, Shimizu Y, Nitta S, Oda H, Ohte Y, et al. The thymic cortical epithelium determines the TCR repertoire of IL-17-producing cdT cells. *EMBO Rep* (2015) 16:638–53. doi:10.15252/embr.201540096
14. Hsu PD, Scott DA, Weinstein JA, Ran FA, Konermann S, Agarwala V, et al. DNA targeting specificity of RNA-guided Cas9 nucleases. *Nat Biotechnol* (2013) 31:827–32. doi:10.1038/nbt.2647
15. Ichii O, Otsuka-Kanazawa S, Horino T, Kimura J, Nakamura T, Matsumoto M, et al. Decreased miR-26a expression correlates with the progression of podocyte injury in autoimmune glomerulonephritis. *PLoS One* (2014) 9:e110383. doi:10.1371/journal.pone.0110383
16. Kanazawa T, Ichii O, Otsuka S, Namiki Y, Hashimoto Y, Kon Y. Hepatocyte nuclear factor 4 alpha is associated with mesenchymal-epithelial transition in developing kidneys of C57BL/6 mice. *J Vet Med Sci* (2011) 73:601–7. doi:10.1292/jvms.10-0493
17. Foster AM, Baliwag J, Chen CS, Guzman AM, Stoll SW, Gudjonsson JE, et al. IL-36 promotes myeloid cell infiltration, activation, and inflammatory activity in skin. *J Immunol* (2014) 192:6053–61. doi:10.4049/jimmunol.1301481
18. Gresnigt MS, van de Veerdonk FL. Biology of IL-36 cytokines and their role in disease. *Semin Immunol* (2013) 25:458–65. doi:10.1016/j.smim.2013.11.003
19. Gabay C, Towne JE. Regulation and function of interleukin-36 cytokines in homeostasis and pathological conditions. *J Leukoc Biol* (2015) 97:645–52. doi:10.1189/jlb.3RI1014-495R
20. Yamanaka K, Nakanishi T, Saito H, Maruyama J, Isoda K, Yokochi A, et al. Persistent release of IL-1s from skin is associated with systemic cardiovascular disease, emaciation and systemic amyloidosis: the potential of anti-IL-1 therapy for systemic inflammatory diseases. *PLoS One* (2014) 9:e104479. doi:10.1371/journal.pone.0104479
21. Ichii O, Yabuki A, Ojima T, Matsumoto M, Taniguchi K, Suzuki S. Immunohistochemical localization of renin, NO synthase-1, and cyclooxygenase-2 in rodent kidney. *Histol Histopathol* (2008) 23:143–50. doi:10.14670/HH-23.143
22. Fujihara CK, Antunes GR, Mattar AL, Andreoli N, Malheiros DM, Noronha IL, et al. Cyclooxygenase-2 (COX-2) inhibition limits abnormal COX-2 expression and progressive injury in the remnant kidney. *Kidney Int* (2013) 64:2172–81. doi:10.1046/j.1523-1755.2003.00319.x
23. O'Neill LA, Golenbock D, Bowie AG. The history of toll-like receptors – redefining innate immunity. *Nat Rev Immunol* (2013) 13:453–60. doi:10.1038/nri3446
24. Ciccia F, Accardo-Palumbo A, Alessandro R, Alessandri C, Priori R, Guggino G, et al. Interleukin-36 α axis is modulated in patients with primary Sjögren's syndrome. *Clin Exp Immunol* (2015) 181:230–8. doi:10.1111/cei.12644
25. Wang M, Wang B, Ma Z, Sun X, Tang Y, Li X, et al. Detection of the novel IL-1 family cytokines by QAH-IL1F-1 assay in rheumatoid arthritis. *Cell Mol Biol (Noisy-le-grand)* (2016) 62:31–4.
26. Chi HH, Hua KF, Lin YC, Chu CL, Hsieh CY, Hsu YJ, et al. IL-36 signaling facilitates activation of the NLRP3 inflammasome and IL-23/IL-17 axis in renal inflammation and fibrosis. *J Am Soc Nephrol* (2017) 28(7):2022–37. doi:10.1681/ASN.2016080840
27. Phillips BM, Milner S, Zouwail S, Roberts G, Cowan M, Riley SG, et al. Severe hyperkalaemia: demographics and outcome. *Clin Kidney J* (2014) 7:127–33. doi:10.1093/ckj/sft158
28. LeBleu VS, Teng Y, O'Connell JT, Charytan D, Müller GA, Müller CA, et al. Identification of human epididymis protein-4 as a fibroblast-derived mediator of fibrosis. *Nat Med* (2013) 19:227–31. doi:10.1038/nm.2989
29. Shepard BD, Pluznick JL. How does your kidney smell? Emerging roles for olfactory receptors in renal function. *Pediatr Nephrol* (2016) 31:715–23. doi:10.1007/s00467-015-3181-8
30. Verghese E, Weidenfeld R, Bertram JF, Ricardo SD, Deane JA. Renal cilia display length alterations following tubular injury and are present early in epithelial repair. *Nephrol Dial Transplant* (2008) 23:834–41. doi:10.1093/ndt/gfm743
31. Wang L, Weidenfeld R, Verghese E, Ricardo SD, Deane JA. Alterations in renal cilium length during transient complete ureteral obstruction in the mouse. *J Anat* (2008) 213:79–85. doi:10.1111/j.1469-7580.2008.00918.x
32. Towne JE, Renshaw BR, Douangpanya J, Lipsky BP, Shen M, Gabel CA, et al. Interleukin-36 (IL-36) ligands require processing for full agonist (IL-36 α , IL-36 β , and IL-36 γ) or antagonist (IL-36Ra) activity. *J Biol Chem* (2011) 286:42594–602. doi:10.1074/jbc.M111.267922
33. Henry CM, Sullivan GP, Clancy DM, Afonina IS, Kulms D, Martin SJ. Neutrophil-derived proteases escalate inflammation through activation of IL-36 family cytokines. *Cell Rep* (2016) 14:708–22. doi:10.1016/j.celrep.2015.12.072
34. Ross R, Grimm J, Goedicke S, Möbus AM, Bulau AM, Bufler P, et al. Analysis of nuclear localization of interleukin-1 family cytokines by flow cytometry. *J Immunol Methods* (2013) 387:219–27. doi:10.1016/j.jim.2012.10.017

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2017 Ichii, Kimura, Okamura, Horino, Nakamura, Sasaki, Elewa and Kon. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.